We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Tuesday said Libtayo showed clinically meaningful and durable responses in second-line advanced basal cell carcinoma in an open-label phase 2 study.
The companies said the study involves patients who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy, for whom there are currently no approved treatments.
Regeneron and Sanofi said they plan to make regulatory filings this year.
Basal cell carcinoma, a skin cancer, is the most common cancer worldwide.
Sanofi and Regeneron last week said they had stopped a pivotal phase 3 trial of Libtayo in advanced non-small cell lung cancer early due to a highly significant improvement in positive overall survival.
Regeneron, of Tarrytown, N.Y., and France's Sanofi are jointly developing and commercializing Libtayo under a global collaboration agreement.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 05, 2020 10:42 ET (14:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
